The probable role of tissue plasminogen activator/neuroserpin axis in Alzheimer’s disease: a new perspective

Abstract

Alzheimer’s disease (AD) is the most common type of dementia associated with amyloid beta (Aβ) deposition. Dysfunction of the neuronal clearance pathway promotes the accumulation of Aβ. The plasminogen-activating system (PAS) is controlled by various enzymes like tissue plasminogen activators (tPA). Neuronal tPA enhances the conversion of plasminogen to plasmin, which cleaves Aβ; this function is controlled by many inhibitors of PAS, including a plasminogen-activating inhibitor (PAI-1) and neuroserpin. Therefore, the objective of the present narrative review was to explore the potential role of tPA/neuroserpin in the pathogenesis of AD. PAI-1 activity is increased in AD, which is involved in accumulating Aβ. Progressive increase of Aβ level during AD neuropathology is correlated with the over-production of PAI-1 with subsequent reduction of plasmin and tPA activities. Reducing plasmin and tPA activities promote Aβ by reducing Aβ clearance. Neuroserpin plays a critical role in the pathogenesis of AD as it regulates the expression and accumulation of Aβ. Higher expression of neuroserpin inhibits the neuroprotective tPA and the generation of plasmin with subsequent reduction in the clearance of Aβ. These observations raise conflicting evidence on whether neuroserpin is neuroprotective or involved in AD progression. Thus, neuroserpin over-expression with subsequent reduction of tPA may propagate AD neuropathology. Graphical abstract

Quantitative Proteomics Reveal Region-Specific Alterations in Neuroserpin-Deficient Mouse Brain and Retina: Insights into Serpini1 Function

“…Here, we detected the dysregulation of thyroid hormone synthesis, mostly in the visual cortex of KO animals, though mediated through other proteins ( Figure 5 ). Interestingly, our interactome analysis suggests the perturbation of proteins involved in amyloid-beta and tau protein regulation which play key roles in neurodegenerative disorders such as AD [ 70 ].…”

BDNF/TrkB activators in Parkinson's disease: A new therapeutic strategy

“…Both Aβ and NFTs alter the synapses and neuronal circuit resulting in cognitive dysfunction and impairment of the synthesis and the release of BDNF from brain neurons. 52 , 53 , 54 In addition, depletion of neuronal BDNF promotes the accumulation of Aβ and NFTs and induces the development of synaptic dysfunction, apoptosis and neuroinflammation. 55 Deficiency of BDNF synthesis is extremely reduced in AD disease due to the progressive intracellular accumulation of NFTs and associated neurodegeneration.…”

Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon

“…Furthermore, AD neuropathology is linked to NFTs, which are caused by hyperphosphorylated tau protein aggregation rather than Aβ (Sengoku 2020 ; Alrouji et al 2023 ; Ali et al 2023 , 2024 ). Tau protein is a small peptide, controls the stability of neuronal microtubules, synaptic plasticity, and axonal transport.…”